Phaseline

Companies › Aprea Therapeutics

Aprea Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
APR-1051
WEE1 inhibitor
WEE1Phase 1Advanced Solid TumorJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06260514APR-1051Phase 1Advanced Solid TumorOncologyJun 2027

From the company's SEC filings

Cash of $38m on 2026-09-30; operating cash outflow about $13m a year; runway about 35 months at that burn, to Aug 2029

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Specialist investors

Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

WEE1 (1)

Companies with the same targets

AstraZeneca K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.